Minerva Neurosciences, Inc. (NERV)
NERV Stock Price Chart
Explore Minerva Neurosciences, Inc. interactive price chart. Choose custom timeframes to analyze NERV price movements and trends.
NERV Company Profile
Discover essential business fundamentals and corporate details for Minerva Neurosciences, Inc. (NERV) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Jul 2014
Employees
8.00
CEO
Remy Luthringer
Description
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
NERV Financial Timeline
Browse a chronological timeline of Minerva Neurosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.19.
Earnings released on 5 May 2026
EPS came in at -$2.86 falling short of the estimated -$0.13 by -2.10k%.
Earnings released on 11 Mar 2026
EPS came in at -$0.64 falling short of the estimated -$0.11 by -481.82%.
Earnings released on 5 Nov 2025
EPS came in at -$0.36 falling short of the estimated -$0.35 by -2.86%.
Earnings released on 14 Aug 2025
EPS came in at -$0.43 surpassing the estimated -$0.95 by +54.74%.
Earnings released on 13 May 2025
EPS came in at -$0.50 surpassing the estimated -$1.07 by +53.27%.
Earnings released on 25 Feb 2025
EPS came in at -$0.56 surpassing the estimated -$1.05 by +46.67%, while revenue for the quarter reached $42.22k .
Earnings released on 5 Nov 2024
EPS came in at $2.97 surpassing the estimated -$1.01 by +394.06%.
Earnings released on 6 Aug 2024
EPS came in at -$1.09 falling short of the estimated -$0.97 by -12.37%.
Earnings released on 1 May 2024
EPS came in at -$1.13 surpassing the estimated -$1.20 by +5.83%.
Earnings released on 22 Feb 2024
EPS came in at -$1.19 falling short of the estimated -$0.88 by -35.23%.
Earnings released on 7 Nov 2023
EPS came in at -$1.03 falling short of the estimated -$0.77 by -33.77%.
Earnings released on 1 Aug 2023
EPS came in at -$1.12 falling short of the estimated -$0.44 by -154.55%.
Earnings released on 15 May 2023
EPS came in at -$1.31 surpassing the estimated -$1.63 by +19.63%.
Earnings released on 8 Mar 2023
EPS came in at -$1.26 surpassing the estimated -$1.35 by +6.67%.
Earnings released on 9 Nov 2022
EPS came in at -$1.29 surpassing the estimated -$1.46 by +11.64%.
Earnings released on 9 Aug 2022
EPS came in at -$1.63 surpassing the estimated -$1.84 by +11.41%.
Stock split effective on 21 Jun 2022
Shares were split 1 : 8 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 4 May 2022
EPS came in at -$1.84 falling short of the estimated -$1.60 by -15.00%.
Earnings released on 1 Mar 2022
EPS came in at -$0.96 surpassing the estimated -$1.60 by +40.00%.
Earnings released on 8 Nov 2021
EPS came in at -$1.76 matching the estimated -$1.76.
Earnings released on 2 Aug 2021
EPS came in at -$2.00 falling short of the estimated -$1.36 by -47.06%.
NERV Stock Performance
Access detailed NERV performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
